Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 831

1.

Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.

Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Brueckmann M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP.

Eur Heart J. 2019 Feb 21. pii: ehz059. doi: 10.1093/eurheartj/ehz059. [Epub ahead of print]

PMID:
30793734
2.

Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.

Cannon CP, Sanchez RJ, Klimchak AC, Khan I, Sasiela WJ, Reynolds MR, Rosenson RS.

Am J Cardiol. 2019 Jan 25. pii: S0002-9149(19)30120-1. doi: 10.1016/j.amjcard.2019.01.028. [Epub ahead of print]

3.

Medication Discontinuation in the IMPROVE-IT Trial.

Navar AM, Roe MT, White JA, Cannon CP, Lokhnygina Y, Newby LK, Giugliano RP, Tershakovec AM, Braunwald E, Califf RM, Blazing MA.

Circ Cardiovasc Qual Outcomes. 2019 Jan;12(1):e005041. doi: 10.1161/CIRCOUTCOMES.118.005041.

PMID:
30630361
4.

Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial.

Wang TY, Kaltenbach LA, Cannon CP, Fonarow GC, Choudhry NK, Henry TD, Cohen DJ, Bhandary D, Khan ND, Anstrom KJ, Peterson ED.

JAMA. 2019 Jan 1;321(1):44-55. doi: 10.1001/jama.2018.19791.

PMID:
30620370
5.

Composite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: The Diabetes Collaborative Registry.

Fan W, Song Y, Inzucchi SE, Sperling L, Cannon CP, Arnold SV, Kosiborod M, Wong ND.

Diabetes Obes Metab. 2019 Jan 4. doi: 10.1111/dom.13625. [Epub ahead of print]

PMID:
30609214
6.

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.

Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, Sambevski S, Kaspers S, Pfarr E, George JT, Zinman B.

Circulation. 2019 Mar 12;139(11):1384-1395. doi: 10.1161/CIRCULATIONAHA.118.037778.

7.

Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE-AF registry.

Contreras JP, Hong KN, Castillo J, Marzec LN, Hsu JC, Cannon CP, Yang S, Maddox TM.

Clin Cardiol. 2019 Mar;42(3):339-345. doi: 10.1002/clc.23142. Epub 2019 Jan 30.

8.

Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention.

Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon DP.

Circulation. 2018 Jul 31;138(5):527-536. doi: 10.1161/CIRCULATIONAHA.118.034722.

PMID:
30571525
9.

Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial).

Vaduganathan M, White WB, Charytan DM, Morrow DA, Liu Y, Zannad F, Cannon CP, Bakris GL; EXAMINE Investigators.

Am J Cardiol. 2019 Feb 1;123(3):382-391. doi: 10.1016/j.amjcard.2018.10.035. Epub 2018 Nov 6.

PMID:
30477800
10.

Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.

Lindholm D, James SK, Gabrysch K, Storey RF, Himmelmann A, Cannon CP, Mahaffey KW, Steg PG, Held C, Siegbahn A, Wallentin L.

JAMA Cardiol. 2018 Nov 14. doi: 10.1001/jamacardio.2018.3811. [Epub ahead of print]

PMID:
30427997
11.

Should real-world evidence be incorporated into regulatory approvals?

Spitzer E, Cannon CP, Serruys PW.

Expert Opin Drug Saf. 2018 Nov 9:1-5. doi: 10.1080/14740338.2018.1546842. [Epub ahead of print] No abstract available.

PMID:
30412009
12.

Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling.

Vaduganathan M, Sathiyakumar V, Singh A, McCarthy CP, Qamar A, Januzzi JL Jr, Scirica BM, Butler J, Cannon CP, Bhatt DL.

J Am Coll Cardiol. 2018 Dec 25;72(25):3370-3372. doi: 10.1016/j.jacc.2018.08.2202. No abstract available.

PMID:
30409566
13.

Reply to: Dual vs. triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.

Golwala H, Cannon CP, Bhatt DL.

Eur Heart J. 2019 Jan 7;40(2):218-219. doi: 10.1093/eurheartj/ehy679. No abstract available.

PMID:
30395259
14.

Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome.

Correa S, Morrow DA, Braunwald E, Davies RY, Goodrich EL, Murphy SA, Cannon CP, O'Donoghue ML.

J Am Heart Assoc. 2018 Oct 16;7(20):e009077. doi: 10.1161/JAHA.118.009077.

15.

Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial.

White WB, Jalil F, Cushman WC, Bakris GL, Bergenstal R, Heller SR, Liu Y, Mehta C, Zannad F, Cannon CP.

J Am Heart Assoc. 2018 Oct 16;7(20):e009114. doi: 10.1161/JAHA.118.009114.

16.

Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials.

Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Eckel RH, Cannon CP, Lee LV, Bessac L, Pordy R, Letierce A, Ray KK.

J Am Heart Assoc. 2018 Sep 18;7(18):e009221. doi: 10.1161/JAHA.118.009221.

17.

WITHDRAWN: Raising the Bar by Lowering the Target: Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management.

Ballantyne CM, Bhatt DL, Cannon CP, Fazio S, Sabatine MS.

Am J Cardiol. 2018 Aug 16. pii: S0002-9149(18)31653-9. doi: 10.1016/j.amjcard.2018.08.020. [Epub ahead of print] No abstract available.

PMID:
30301542
18.

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).

Cannon CP, McGuire DK, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Charbonnel B, Shih WJ, Gallo S, Masiukiewicz U, Golm G, Cosentino F, Lauring B, Terra SG; VERTIS-CV Investigators.

Am Heart J. 2018 Dec;206:11-23. doi: 10.1016/j.ahj.2018.08.016. Epub 2018 Sep 5.

19.

Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials.

Berg DD, Wiviott SD, Braunwald E, Guo J, Im K, Kashani A, Gibson CM, Cannon CP, Morrow DA, Bhatt DL, Mega JL, O'Donoghue ML, Antman EM, Newby LK, Sabatine MS, Giugliano RP.

Eur Heart J. 2018 Nov 7;39(42):3810-3820. doi: 10.1093/eurheartj/ehy556.

PMID:
30239711
20.

Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status.

Ambrosy AP, Cerbin LP, Fudim M, Clare RM, Lokhnygina Y, Braunwald E, Califf RM, Cannon CP, Tershakovec AM, Roe MT, Blazing MA.

Am J Cardiol. 2018 Nov 1;122(9):1451-1458. doi: 10.1016/j.amjcard.2018.07.034. Epub 2018 Aug 4.

PMID:
30180960
21.

The Evolving Future of PCSK9 Inhibitors.

Rosenson RS, Hegele RA, Fazio S, Cannon CP.

J Am Coll Cardiol. 2018 Jul 17;72(3):314-329. doi: 10.1016/j.jacc.2018.04.054. Epub 2018 Jul 9. Review.

PMID:
30012326
22.

High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial.

Vardeny O, Udell JA, Joseph J, Farkouh ME, Hernandez AF, McGeer AJ, Talbot HK, Bhatt DL, Cannon CP, Goodman SG, Anand I, DeMets DL, Temte J, Wittes J, Nichol K, Yancy CW, Gaziano JM, Cooper LS, Kim K, Solomon SD.

Am Heart J. 2018 Aug;202:97-103. doi: 10.1016/j.ahj.2018.05.007. Epub 2018 May 23.

PMID:
29909156
23.

The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe.

Simon TG, Corey KE, Cannon CP, Blazing M, Park JG, O'Donoghue ML, Chung RT, Giugliano RP.

Int J Cardiol. 2018 Nov 1;270:245-252. doi: 10.1016/j.ijcard.2018.05.087. Epub 2018 May 26.

PMID:
29903515
24.

Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".

Bohula EA, Wiviott SD, Giugliano RP, Park JG, Murphy SA, Cannon CP, Braunwald E.

Circulation. 2018 Jun 12;137(24):2662-2663. doi: 10.1161/CIRCULATIONAHA.118.034500. No abstract available.

PMID:
29891625
25.

Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis.

Scirica BM, Bansilal S, Davoudi F, Armstrong PW, Clare RM, Schulte PJ, Pieper KS, Becker RC, James SK, Storey RF, Steg PG, Held C, Himmelmann A, Mahaffey KW, Wallentin L, Cannon CP; PLATO Steering Committee and Investigators.

Am Heart J. 2018 Aug;202:54-60. doi: 10.1016/j.ahj.2018.04.020. Epub 2018 May 7.

PMID:
29859968
26.

Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial.

Jarolim P, White WB, Cannon CP, Gao Q, Morrow DA.

Diabetes Care. 2018 Jul;41(7):1510-1515. doi: 10.2337/dc18-0109. Epub 2018 May 30.

PMID:
29848776
27.

Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events.

Lee S, Cannon CP.

Curr Cardiol Rep. 2018 May 25;20(7):55. doi: 10.1007/s11886-018-0997-4. Review.

PMID:
29802475
28.

A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU Trial.

Reynolds MR, Allison JS, Natale A, Weisberg IL, Ellenbogen KA, Richards M, Hsieh WH, Sutherland J, Cannon CP.

JACC Clin Electrophysiol. 2018 May;4(5):580-588. doi: 10.1016/j.jacep.2017.11.005. Epub 2017 Dec 20.

PMID:
29798783
29.

Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies.

Ginsberg HN, Farnier M, Robinson JG, Cannon CP, Sattar N, Baccara-Dinet MT, Letierce A, Bujas-Bobanovic M, Louie MJ, Colhoun HM.

Diabetes Ther. 2018 Jun;9(3):1317-1334. doi: 10.1007/s13300-018-0439-8. Epub 2018 May 19.

30.

Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.

Sharma A, Cannon CP, White WB, Liu Y, Bakris GL, Cushman WC, Zannad F.

J Am Heart Assoc. 2018 May 16;7(11). pii: e007649. doi: 10.1161/JAHA.117.007649.

32.

Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial.

Bergmark BA, Udell JA, Morrow DA, Cannon CP, Steen DL, Jarolim P, Budaj A, Hamm C, Guo J, Im K, Kuder JF, Braunwald E, Sabatine MS, O'Donoghue ML.

JAMA Cardiol. 2018 Jun 1;3(6):473-480. doi: 10.1001/jamacardio.2018.0653.

PMID:
29710336
33.

Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials.

Golwala HB, Cannon CP, Steg PG, Doros G, Qamar A, Ellis SG, Oldgren J, Ten Berg JM, Kimura T, Hohnloser SH, Lip GYH, Bhatt DL.

Eur Heart J. 2018 May 14;39(19):1726-1735a. doi: 10.1093/eurheartj/ehy162.

34.

Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome.

Cavender MA, White WB, Liu Y, Massaro JM, Bergenstal RM, Mehta CR, Zannad F, Heller S, Cushman WC, Cannon CP.

Clin Cardiol. 2018 Aug;41(8):1022-1027. doi: 10.1002/clc.22960. Epub 2018 Aug 16.

35.

Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial.

White WB, Heller SR, Cannon CP, Howitt H, Khunti K, Bergenstal RM; EXAMINE Investigators.

Am J Med. 2018 Jul;131(7):813-819.e5. doi: 10.1016/j.amjmed.2018.02.023. Epub 2018 Mar 23.

PMID:
29581078
36.

Individualizing Blood Pressure Targets for People With Diabetes and Hypertension: Comparing the ADA and the ACC/AHA Recommendations.

de Boer IH, Bakris G, Cannon CP.

JAMA. 2018 Apr 3;319(13):1319-1320. doi: 10.1001/jama.2018.0642. No abstract available.

PMID:
29543954
37.

Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome.

Cavallari I, Cannon CP, Braunwald E, Goodrich EL, Im K, Lukas MA, O'Donoghue ML.

Eur J Prev Cardiol. 2018 May;25(8):830-838. doi: 10.1177/2047487318763897. Epub 2018 Mar 14.

PMID:
29537291
38.

Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.

Toth PP, Dwyer JP, Cannon CP, Colhoun HM, Rader DJ, Upadhyay A, Louie MJ, Koren A, Letierce A, Mandel J, Banach M.

Kidney Int. 2018 Jun;93(6):1397-1408. doi: 10.1016/j.kint.2017.12.011. Epub 2018 Mar 8.

39.

Sustained sex-based treatment differences in acute coronary syndrome care: Insights from the American Heart Association Get With The Guidelines Coronary Artery Disease Registry.

Udell JA, Fonarow GC, Maddox TM, Cannon CP, Frank Peacock W, Laskey WK, Grau-Sepulveda MV, Smith EE, Hernandez AF, Peterson ED, Bhatt DL; Get With The Guidelines Steering Committee and Investigators.

Clin Cardiol. 2018 Jun;41(6):758-768. doi: 10.1002/clc.22938. Epub 2018 May 11.

40.

PCSK9 inhibitor valuation: A science-based review of the two recent models.

Baum SJ, Cannon CP.

Clin Cardiol. 2018 Apr;41(4):544-550. doi: 10.1002/clc.22924. Epub 2018 Mar 7. Review.

41.

Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction.

Ibrahim NE, Gaggin HK, Turchin A, Patel HK, Song Y, Trebnick A, Doros G, Maya JF, Cannon CP, Januzzi JL.

Eur Heart J Cardiovasc Pharmacother. 2019 Jan 1;5(1):3-11. doi: 10.1093/ehjcvp/pvy011.

PMID:
29490032
42.

Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study.

Storey RF, Ardissino D, Vignali L, Cairns R, Becker RC, Cannon CP, Mahaffey KW, Himmelmann A, Katus HA, James SK, Wallentin L; PLATO Investigators.

Thromb Haemost. 2018 Feb;118(2):427-429. doi: 10.1160/TH17-05-0355. Epub 2018 Jan 29. No abstract available.

PMID:
29443375
43.

Addition or removal of guideline directed medical therapy in ambulatory patients with heart failure with reduced ejection fraction relative to change in symptom severity: An analysis from the PINNACLE (Practice Innovation and Clinical Excellence) Registry®.

Ibrahim NE, Song Y, Cannon CP, Doros G, Trebnick A, Russo P, Ponirakis A, Alexanian C, Januzzi JL Jr.

Int J Cardiol. 2018 Mar 1;254:222-223. doi: 10.1016/j.ijcard.2017.10.096. Epub 2018 Jan 28. No abstract available. Retraction in: Int J Cardiol. 2018 Mar 1;254:R1.

PMID:
29407094
44.

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.

Cannon CP, Lip GYH, Oldgren J.

N Engl J Med. 2018 Feb 1;378(5):485-486. doi: 10.1056/NEJMc1715183. No abstract available.

PMID:
29385366
45.

Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes.

Garlo KG, White WB, Bakris GL, Zannad F, Wilson CA, Kupfer S, Vaduganathan M, Morrow DA, Cannon CP, Charytan DM.

Clin J Am Soc Nephrol. 2018 Mar 7;13(3):398-405. doi: 10.2215/CJN.05280517. Epub 2018 Jan 16.

46.

The effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: Insights from PROVE IT-TIMI 22.

Steen DL, Umez-Eronini AA, Guo J, Khan N, Cannon CP.

Clin Cardiol. 2018 Jan;41(1):68-73. doi: 10.1002/clc.22851. Epub 2017 Dec 28.

47.

Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).

Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Špinar J, Park JG, White JA, Bohula EA, Braunwald E; IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators.

Circulation. 2018 Apr 10;137(15):1571-1582. doi: 10.1161/CIRCULATIONAHA.117.030950. Epub 2017 Dec 20.

PMID:
29263150
48.

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.

Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V; CREDENCE study investigators.

Am J Nephrol. 2017 Dec 13;46(6):462-472. doi: 10.1159/000484633. [Epub ahead of print]

49.

Association of insurance type with receipt of oral anticoagulation in insured patients with atrial fibrillation: A report from the American College of Cardiology NCDR PINNACLE registry.

Yong CM, Liu Y, Apruzzese P, Doros G, Cannon CP, Maddox TM, Gehi A, Hsu JC, Lubitz SA, Virani S, Turakhia MP; ACC PINNACLE Investigators.

Am Heart J. 2018 Jan;195:50-59. doi: 10.1016/j.ahj.2017.08.010. Epub 2017 Aug 31.

PMID:
29224646
50.

Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).

Kato ET, Cannon CP, Blazing MA, Bohula E, Guneri S, White JA, Murphy SA, Park JG, Braunwald E, Giugliano RP.

J Am Heart Assoc. 2017 Nov 18;6(11). pii: e006901. doi: 10.1161/JAHA.117.006901.

Supplemental Content

Loading ...
Support Center